Mankyu Park

SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA.

Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.

Bayer HealthCare Pharmaceuticals, Inc. manufactures pharmaceutical drugs. It offers pharmaceuticals and therapeutics in the areas of diagnostic imaging, hematology and cardiology, cancer, women's health and several other chronic diseases such as multiple sclerosis and Parkinson's disease. Bayer HealthCare Pharmaceuticals was founded in 1979 and is located in Wayne, NJ.

Part of Pfizer Inc., Ignite Immunotherapy, Inc. is a company that designs and develops oncolytic virus vaccines. The company is based in New York, NY. The company was founded by David Schaffer, Douglas Hanahan, David H. Kirn, Theresa Janke, Melissa Kotterman. The CEO is Monika A. Vnuk.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Specialist Diabetes Research & Treatment Centre LLC specializes in diabetes treatment, research, training and public health awareness. Its services include diabetes, endocrinology, bariatric & metabolic, antenatal, cardiology, nephrology, podiatry, ophthalmology, radiology, dietetic services, laboratory, and pharmacy. The company was founded in May 2006 and is headquartered Abu Dhabi, United Arab Emirates.

IP2IPO Innovations Ltd. provides business development and technology transfer services. The firm also provides strategic industry University partnerships, patenting, licensing, spin-out incubation and equity management services. The company was founded in 1986 and is headquartered in London, the United Kingdom.

National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD.

Ocuterra Therapeutics, Inc. manufactures drug products. The company is headquartered in Boston, MA.

Nacuity Pharmaceuticals, Inc. develops and markets pharmaceutical products. The company is headquartered in Fort Worth, TX.

Alveo Technologies, Inc. operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices. The company was founded by Ron Chiarello, Michael A. Aicher, Lawrence M. Blatt and Sumita Pennathur in 2014 and is headquartered in Alameda, CA.

Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA.

Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye.